These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

252 related items for PubMed ID: 15979942

  • 1. Antigen-specific CD8+ T lymphocytes generated from a DNA vaccine control tumors through the Fas-FasL pathway.
    Cheng WF, Lee CN, Chang MC, Su YN, Chen CA, Hsieh CY.
    Mol Ther; 2005 Nov; 12(5):960-8. PubMed ID: 15979942
    [Abstract] [Full Text] [Related]

  • 2. CD8+ T cells, NK cells and IFN-gamma are important for control of tumor with downregulated MHC class I expression by DNA vaccination.
    Cheng WF, Hung CF, Lin KY, Ling M, Juang J, He L, Lin CT, Wu TC.
    Gene Ther; 2003 Aug; 10(16):1311-20. PubMed ID: 12883527
    [Abstract] [Full Text] [Related]

  • 3. Naked RNA vaccine controls tumors with down-regulated MHC class I expression through NK cells and perforin-dependent pathways.
    Cheng WF, Hung CF, Lee CN, Su YN, Chang MC, He L, Wu TC, Chen CA, Hsieh CY.
    Eur J Immunol; 2004 Jul; 34(7):1892-900. PubMed ID: 15214037
    [Abstract] [Full Text] [Related]

  • 4. Comparison of HPV DNA vaccines employing intracellular targeting strategies.
    Kim JW, Hung CF, Juang J, He L, Kim TW, Armstrong DK, Pai SI, Chen PJ, Lin CT, Boyd DA, Wu TC.
    Gene Ther; 2004 Jun; 11(12):1011-8. PubMed ID: 14985791
    [Abstract] [Full Text] [Related]

  • 5. DNA vaccine encoding heat shock protein 60 co-linked to HPV16 E6 and E7 tumor antigens generates more potent immunotherapeutic effects than respective E6 or E7 tumor antigens.
    Huang CY, Chen CA, Lee CN, Chang MC, Su YN, Lin YC, Hsieh CY, Cheng WF.
    Gynecol Oncol; 2007 Dec; 107(3):404-12. PubMed ID: 17905417
    [Abstract] [Full Text] [Related]

  • 6. Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin.
    Hsieh CJ, Kim TW, Hung CF, Juang J, Moniz M, Boyd DA, He L, Chen PJ, Chen CH, Wu TC.
    Vaccine; 2004 Sep 28; 22(29-30):3993-4001. PubMed ID: 15364449
    [Abstract] [Full Text] [Related]

  • 7. Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen.
    Cheng WF, Hung CF, Chai CY, Hsu KF, He L, Ling M, Wu TC.
    J Clin Invest; 2001 Sep 28; 108(5):669-78. PubMed ID: 11544272
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Recombinant DNA vaccines protect against tumors that are resistant to recombinant vaccinia vaccines containing the same gene.
    Chen CH, Wang TL, Ji H, Hung CF, Pardoll DM, Cheng WF, Ling M, Wu TC.
    Gene Ther; 2001 Jan 28; 8(2):128-38. PubMed ID: 11313782
    [Abstract] [Full Text] [Related]

  • 14. Gene gun-mediated DNA vaccination induces antitumor immunity against human papillomavirus type 16 E7-expressing murine tumor metastases in the liver and lungs.
    Chen CH, Ji H, Suh KW, Choti MA, Pardoll DM, Wu TC.
    Gene Ther; 1999 Dec 28; 6(12):1972-81. PubMed ID: 10637448
    [Abstract] [Full Text] [Related]

  • 15. Enhancement of DNA vaccine potency through linkage of antigen gene to ER chaperone molecules, ER-60, tapasin, and calnexin.
    Lin CT, Chang TC, Chao A, Dzeng E, Soong YK, Hung CF, Lai CH.
    J Biomed Sci; 2005 Dec 28; 12(2):279-87. PubMed ID: 15918000
    [Abstract] [Full Text] [Related]

  • 16. Characterization of HPV-16 E6 DNA vaccines employing intracellular targeting and intercellular spreading strategies.
    Peng S, Trimble C, Ji H, He L, Tsai YC, Macaes B, Hung CF, Wu TC.
    J Biomed Sci; 2005 Oct 28; 12(5):689-700. PubMed ID: 16200349
    [Abstract] [Full Text] [Related]

  • 17. Deoxyribonucleic acid (DNA) encoding a pan-major histocompatibility complex class II peptide analogue augmented antigen-specific cellular immunity and suppressive effects on tumor growth elicited by DNA vaccine immunotherapy.
    Teramoto K, Kontani K, Ozaki Y, Sawai S, Tezuka N, Nagata T, Fujino S, Itoh Y, Taguchi O, Koide Y, Asai T, Ohkubo I, Ogasawara K.
    Cancer Res; 2003 Nov 15; 63(22):7920-5. PubMed ID: 14633722
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Impaired antigen presentation and effectiveness of combined active/passive immunotherapy for epithelial tumors.
    Matsumoto K, Leggatt GR, Zhong J, Liu X, de Kluyver RL, Peters T, Fernando GJ, Liem A, Lambert PF, Frazer IH.
    J Natl Cancer Inst; 2004 Nov 03; 96(21):1611-9. PubMed ID: 15523090
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.